Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

PartnershipImmuneSelectPositive

AI Analysis

Summary

Virax Biolabs CEO provided a shareholder update following the fiscal 2026 annual report showing $6.4 million in cash and total assets of $8.3 million, along with announcement of a commercial supply agreement with Fosun Diagnostics for ImmuneSelect.

Outcome Details

Commercial supply agreement with Fosun Diagnostics for ImmuneSelect

Importance:4/10

Sentiment:

0.40

shareholder updatepartnershipcommercial agreementfinancial position

Read the original article

Published by PR Newswire Biotech on July 16, 2026 11:30 AM

Read Original